Discovery of 2-aminopyridine Derivatives with Antichagasic and Antileishmanial Activity Using Phenotypic Assays

Author(s): Daiane Yukie Tezuka, Sergio de Albuquerque, Carlos Alberto Montanari, Andrei Leitão*.

Journal Name: Letters in Drug Design & Discovery

Volume 17 , Issue 7 , 2020

Become EABM
Become Reviewer


Background: Compounds previously studied as anticancer were screened against trypomastigotes to access the bioactivity. The epimastigote form of Trypanosoma cruzi Y strain and the promastigote form of Leishmania amazonensis and Leishmania infantum were used in this work.

Methods: Cell-based assays were performed to access the bioactivity of the compounds using MTT and the flow cytometry methods.

Results: Neq0438, Neq0474 and Neq0440 had the highest potency, with EC50 of 39 μM (L. amazonensis), 52 μM (T. cruzi) and 81 μM (T. cruzi), respectively. These molecules were inactive for Balb/C fibroblast cell line at concentrations above 250 μM, showing selectivity for the parasites.

Conclusion: This is the first report that demonstrates antiparasitic activity for the 2-aminopyridine scaffold, with cross-activity against cancer cells.

Keywords: Trypanosoma cruzi, leishmania infantum, leishmania amazonensis, cell-based assays, selectivity index, antiparasitic compounds.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [867 - 872]
Pages: 6
DOI: 10.2174/1570180816666191204105232
Price: $95

Article Metrics

PDF: 2